Galena Biopharma Inc (GALE) Receives "Outperform" Rating from Oppenheimer


's stock had its "outperform" rating restated by equities research analysts at Oppenheimer in a research report issued to clients and investors on Friday, MarketBeat reports. They currently have a $4.00 price objective on the biotechnology company's stock.



from Biotech News